Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease

Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease / Fiorino, G; Ruiz-Arguello, Mb; Maguregui, A; Nagore, D; Correale, C; Radice, S; Gilardi, D; Allocca, M; Furfaro, F; Martinez, A; Danese, S. - In: INFLAMMATORY BOWEL DISEASES. - ISSN 1078-0998. - 24:3(2018), pp. 601-606. [10.1093/ibd/izx086]